This author has yet to write their bio.Meanwhile lets just say that we are proud Business Wire contributed a whooping 641 entries.
Javelin Biotech announced a three-year collaboration with Pfizer to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules.
MJH Life Sciences™ Launches COVID-19 Coalition — Alliance of renowned thought leaders to assemble biweekly to keep health care professionals abreast of emerging COVID-19 science and news. September 10, 2020 11:46 AM Eastern Daylight Time CRANBURY, N.J.–(BUSINESS WIRE)–MJH Life Sciences™, the privately owned health care media company, is pleased to officially announce […]
The U.S. Food and Drug Administration approved MorphoSys and Incyte’s Monjuvi (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
Bristol Myers Squibb and bluebird bio announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.
This panel discussion will feature the top minds in infectious diseases, virology and vaccinology, who will give participants a breakdown of the top vaccine candidates and the latest information on clinical trials.
W2O, a leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector, announced the acquisition of Discern Health.
The U.S. Food and Drug Administration granted accelerated approval to Gilead Company Kite’s Tecartus (brexucabtagene autoleucel, formerly KTE-X19) as the first approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the expanded approval of Kyowa Kirin Co. Ltd.’s Crysvita (burosumab) to include older adolescents and adults living with the rare disease X-linked hypophosphatemia.
The U.S. Food and Drug Administration approved MC2 Therapeutics’ Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older.
The U.S. Food and Drug Administration accepted the filing of Aurinia Pharmaceuticals Inc.’s New Drug Application (NDA) for voclosporin as a potential treatment for lupus nephritis, a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus.